Join
Live feed
·
PRReleasevia Quantisnow
BioMarin Pharmaceutical Inc. logo

BioMarin Announces 28% Y/Y Total Revenue Growth in the Third Quarter and Increase in Full-year 2024 Guidance; Reaffirms Long-term Guidance and Outlook

ByQuantisnow·Wall Street's wire, on your screen.
BMRN· BioMarin Pharmaceutical Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track BMRN (BioMarin Pharmaceutical Inc.) and more on Quantisnow.